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vestigation was performed to determine whether the in-
troduction of salmeterol to moderate-to-severe asthmat-
ics in a Medicaid fee-for-service population reduces the
overall asthma related health care expenditures. METH-
ODS: The New Mexico Medicaid fee-for-service claims
database was searched between 1/1/94 and 12/31/98 to
identify both a salmeterol and control group. The inclu-
sion criteria for the salmeterol group were: patients re-
ceiving salmeterol, who were 66% compliant with salme-
terol therapy, had a diagnosis of asthma (ICD-9: 493.0,
493.1, 493.9), were 13 years of age or older, did not have
a diagnosis of COPD (ICD-9: 496.x) and must have been
Medicaid eligible for 2 consecutive years. In addition to
the above criteria for the salmeterol group, to be included
in the control group, patients must not have received sal-
meterol between 4/12/95 and 4/12/97 (around the me-
dian start date of salmeterol, 4/12/96), and in order to
match for severity must have received other asthma
maintenance medications. Patients meeting these criteria
for the salmeterol and control groups were 57 and 58, re-
spectively. ANCOVA were performed to compare costs
between the two groups controlling for baseline costs.
Average per patient benefit-cost ratios were calculated by
dividing total cost savings by increase in medication costs
for both groups. RESULTS: No significant difference ex-
isted among average per patient total health care expen-
ditures between the salmeterol and control groups ($2266
and $1955, respectively). Interestingly, in the salmeterol
group, total medication costs increased significantly (t 
7.895, p  0.000) while total health care costs de-
creased, although not significantly. The average per pa-
tient benefit-cost ratio for the salmeterol group was
0.061 ($41/$668). CONCLUSION: Introduction of sal-
meterol in the New Mexico Medicaid fee-for-service pop-
ulation did not significantly reduce total asthma related
health care costs.
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OBJECTIVES: To compare effectiveness of compliance
on health care utilization between montelukast and stan-
dard therapy (inhaled corticosteroid—ICS) patients. Indi-
cators for health care resource use include drug use, ER
visits, and total charges. METHODS: Retrospective co-
hort analysis using LifeLink employer claims database of
1.6 million Americans. ANOVA models examined health
care resource use of montelukast and ICS patients in six
months prior (pre-period) and six month following (post-
period) new treatment of interest adjusting for age, gen-
der, region, plan type, and prescriber specialty. RE-
SULTS: The study cohort consisted of 3,775 montelukast
patients and 7,331 ICS patients. Average compliance, de-
fined as medication possession ratio, of montelukast pa-
tients (63%) was significantly greater (p  0.001) than
that of ICS patients (31%). Montelukast patients were
more likely to receive short-acting beta-agonist therapy in
pre-period than ICS patients (p  0.001), which suggests
more severe patients in montelukast group, but there was
no significant difference between two groups in post-
period (p  0.854). Among patients with concomitant
methylxanthine therapy, montelukast patients had more
days of methylxanthine therapy than ICS in pre-period
(p  0.001), but there was no significant difference in
post-period (p  0.130). For patients with at least one
asthma-related ER visit, montelukast patients had more
ER visits per patient than ICS patients in pre-period (p 
0.010), but no significant difference was noted in post-
period (p  0.325). Average total charges for montelukast
were higher than for ICS patients in both pre-period (p 
0.001) and post-period (p  0.001). CONCLUSIONS:
Compliance with montelukast treatment was markedly
better than with ICS therapy. Initially, montelukast pa-
tients were higher resource users than ICS patients. Dur-
ing six months treatment with montelukast, some health
care resources used decreased to the level of ICS patients.
Results suggest that markedly improved compliance of
montelukast decreased asthma-related health care utiliza-
tion, however total charges for montelukast patients re-
mained higher than for ICS patients.
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Preliminary pharmacoeconomic analyses suggest that
levalbuterol (LEV) therapy is associated with decreased
outpatient asthma health care costs. OBJECTIVE: Exam-
ine treatment costs in asthma patients stratified by the
number of prescribed controller medications (CM), an in-
dex of asthma severity. METHODS: Claims data on pa-
tients prescribed LEV and RAC were obtained from the
PharMetrics Integrated Outcomes Database. Age- and
sex-matched samples of patients initiating therapy with
LEV or RAC (no prescriptions for either agent in prior 6
months) were selected and their asthma-related charges
were assessed over 6 months following the initial pre-
scription. RESULTS: 544 LEV-treated patients were
identified and matched to 544 RAC-treated patients.
62% of RAC patients previously received no CM, 20%
had 1 CM, and 18% had 1 CM. Following RAC treat-
ment 30% had 1 CM and 29% had 1 CM. Use of leu-
kotriene modifiers increased from 8% to 14% and corti-
costeroid use increased from 33% to 46%. Although
